Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus

No significant differences in treatment effects for major adverse cardiovascular events (MACE) were observed between Asian and White patients with type 2 diabetes mellitus (T2DM).

• 22 publications from 13 randomized trials were included in the analysis.
• For MACE, glucagon-like peptide-1 receptor agonists (GLP-1 RA) showed a hazard ratio of 0.84 (95% CI: 0.68-1.04) in Asian versus White patients.
• Sodium-glucose cotransporter-2 inhibitors (SGLT2i) had a hazard ratio of 0.90 (95% CI: 0.72-1.13) for MACE, indicating no differences by race.
• No differences in the treatment effects of SGLT2i on kidney outcomes were found, with a hazard ratio of 1.01 (95% CI: 0.75-1.36).
• The study found no significant effect modification by race on cardiovascular and kidney outcomes.

AI simplified